Hypoxia is a potent coronary-vasodilating signal; its mechanisms are still controversial. We have assessed the possible role of nitric oxide (NO) in hypoxic coronary vasodilatation (HCVD) in isolated guinea pig hearts perfused at constant pressure. HCVD was elicited by a 1-minute 100o N2 exposure; coronary flow doubled within 1 minute of hypoxia (early phase) and returned to baseline within 40 seconds after reoxygenation (late phase). The early phase of HCVD was associated with a rapid approximately eightfold increase in cGMP overflow, an indication of NO release. The specific NO synthase inhibitor N'-methyl-L-arginine (NMA, 0.1-1 mM) antagonized HCVD and the associated increase in cGMP spillover (maximum inhibition, =65%); excess arginine (1.2 mM) prevented both effects. The late phase of HCVD was associated with an increase in adenosine overflow and was attenuated by the adenosine receptor antagonist BW A1433 (1 ,M; maximum inhibition, :45%). Indomethacin (10 ,uM) inhibited HCVD in spontaneously beating hearts by =35% but had no effect in hearts paced at faster rates. NMA and BW A1433 were more effective in combination than alone (maximum inhibition, =72%). However, irrespective of the concentrations used, there was no synergism among the anti-HCVD effects of NMA, BW A1433, and indomethacin, nor was HCVD completely inhibited by the antagonists, whether alone or in combination. of adenosine within the heart.8 Thus, other endogenous vasodilators are likely to play a role in HCVD. Although the earlier literature tended to discount the role of vasodilating prostaglandins in HCVD,9-11 more recent evidence suggests that the relaxation of coronary vessels in response to hypoxic stimuli is mediated at least in part by prostaglandin release.12-14 However, neither adenosine nor prostaglandins seem to account for HCVD in its entirety, and other mechanisms have been proposed, such as increased production of the vasodilator ATP15 and hyperpolarization of coronary vascular smooth muscle via the opening of ATP-sensitive K' channels. 16 Since its discovery as an endothelium-derived relaxing factor17 and its identification as nitric oxide (NO),1819 it has been demonstrated both by us20 and others21 that NO is released from the coronary endothelium and modulates coronary vascular tone. Inasmuch as hypoxia stimulates the release of endotheliumderived relaxing factor from aortic and femoral artery endothelium,22 it is plausible that a decrease in oxygen tension will also promote the release of NO from the coronary vasculature and that this autacoid will contribute to the increase in coronary flow that is associated with hypoxia. Thus, the purpose of our investigation was to establish whether NO production is increased in the hypoxic heart and to assess the possible role of this
It is generally agreed that hypoxia has a strong vasodilating effect on the coronary circulation.1 Yet the mechanisms by which coronary arteries dilate when oxygen tension decreases are still at issue. Much attention has been devoted in the past to the possible role of vasodilatatory metabolites, and adenosine has long been considered an important mediator of coronary vasomotion in response to lowered oxygen tension. 23 Adenosine is released from endothelial cells and myocytes of hypoxic hearts and reaches vasoactive concentrations in the coronary effluent.4-6 Nevertheless, there are indications that coronary vasodilatation in response to acute hypoxia is not solely dependent on adenosine. Indeed, the time course of hypoxic coronary vasodilatation (HCVD) has been found not to coincide with that of adenosine release,7 and no reduction of of adenosine within the heart.8 Thus, other endogenous vasodilators are likely to play a role in HCVD.
Although the earlier literature tended to discount the role of vasodilating prostaglandins in HCVD,9-11 more recent evidence suggests that the relaxation of coronary vessels in response to hypoxic stimuli is mediated at least in part by prostaglandin release.12-14 However, neither adenosine nor prostaglandins seem to account for HCVD in its entirety, and other mechanisms have been proposed, such as increased production of the vasodilator ATP15 and hyperpolarization of coronary vascular smooth muscle via the opening of ATP-sensitive K' channels. 16 Since its discovery as an endothelium-derived relaxing factor17 and its identification as nitric oxide (NO),1819 it has been demonstrated both by us20 and others21 that NO is released from the coronary endothelium and modulates coronary vascular tone. Inasmuch as hypoxia stimulates the release of endotheliumderived relaxing factor from aortic and femoral artery endothelium, 22 it is plausible that a decrease in oxygen tension will also promote the release of NO from the coronary vasculature and that this autacoid will contribute to the increase in coronary flow that is associated with hypoxia. Thus, the purpose of our investigation was to establish whether NO production is increased in the hypoxic heart and to assess the possible role of this autacoid as a mediator of HCVD. Because of the controversy surrounding the role of other putative mediators, we have also sought to investigate the relation of NO release and actions to those of adenosine and vasodilatatory prostaglandins.
Materials and Methods Isolated Heart Perfusion
Male Hartley guinea pigs (Hilltop, Pa.) weighing 250-300 g were killed by cervical dislocation under light anesthesia with CO2 vapor. After midline thoracotomy, the heart was rapidly excised and perfused retrogradely at a constant pressure of 45 When hypoxia was induced in the presence of pharmacological agents, hearts were continuously perfused with a given drug at the desired concentration for a 20-minute period before the induction of hypoxia. In some experiments, adenosine was administered to isolated hearts by rapid intra-aortic bolus injection in a volume of 300 ,lI.
Adenosine Assay
Adenosine and inosine were assayed by reverse-phase high-performance liquid chromatography according to the method of Jenkins Figure 1B , the hypoxic response of spontaneously beating hearts did not differ from that of hearts paced at constant rate, and the two curves were almost identical.
HCVD in the Isolated Guinea Pig Heart: Modification by NO 
Synthase Inhibition
The specific NO synthase inhibitor NMA (0.1-1 mM) antagonized HCVD as a function of its concentration. A maximum inhibition of 66.5+9.2% was reached with 1 mM NMA ( Figure 2A) ; the overall 2-minute inhibition (calculated from the areas under the two curves describing the hypoxic increases in coronary flow rate in control and NMA-treated conditions) was reduced by 64.2±5.4%. Although perfusion with an excess of L-arginine (1.2 mM) had no effect on the magnitude of the hypoxic vasodilatatory response, it did prevent the inhibitory effect of NMA ( Figure 2A ). This suggested that arginine-derived NO mediates, at least in part, the vasodilatatory response to hypoxia.
Nevertheless, inasmuch as coronary vasodilatation leads to an increase in flow and hence intravascular shear, which is a recognized NO-releasing signal,'2 it had to be excluded that the increase in coronary flow in response to hypoxia might be the cause of NO release instead of its effect. Thus, we also assessed whether NO is released in response to hypoxia when flow is kept constant. Isolated guinea pig hearts were perfused at a constant flow of 6.5 ml/min with Ringer's solution bubbled with 100% 02. When hearts were perfused for 1 minute with Ringer's solution bubbled with 100% N2, a marked coronary vasodilation occurred, as indicated by a decrease in coronary perfusion pressure of z30 mm Hg (i.e., a 50% decrease; Figure 2B ). In the presence of NMA (300 ,uM), the decrease in perfusion pressure in response to hypoxia was reduced to one half. In fact, 300 ,M NMA caused a 55% inhibition of HCVD in hearts perfused at constant flow as compared with a 48% inhibition in hearts perfused at constant pressure. Excess arginine was as effective in preventing the inhibitory effect of NMA in hearts perfused at constant flow as it was in hearts perfused at constant pressure (compare panels A and B in Figure 2 ). Hence, these findings lended further support to our postulate that arginine-derived NO is a mediator of HCVD.
Yet, inasmuch as NMA by itself caused a decrease in coronary flow rate (Table 1) , the possibility had to be ruled out that vasoconstriction per se might be responsible for NMA's inhibition of hypoxic vasodilatation. To test this, we induced coronary vasoconstriction by perfusing hearts with the thromboxane analogue U46619. At a concentration of 57 nM, compound U46619 caused -60% reduction in coronary flow; yet, as shown in Figure 3A , HCVD was unaffected both in magnitude and duration.
HCVD: Release of NO production is enhanced during hypoxia. We measured the cGMP content of coronary effluents of hearts exposed to hypoxia as a marker of NO production. As shown in Figure 3 , the overflow of cGMP into the coronary effluent increased approximately eightfold in the first minute of hypoxia and was associated with a doubling of coronary flow rate; cGMP release subsequently declined in the first minute of return to 100% oxygen perfusion while coronary flow reverted to con- (Figures 3A and 3B ). Excess L-arginine (1.2 mM), which prevented the NMA-induced inhibition of HCVD (Figure 2 ), also prevented NMA from inhibiting the hypoxic increase in cGMP overflow into the coronary effluent ( Figure 3B ).
Since adenosine is produced in large quantities by cardiac myocytes in hypoxic conditions and this nucleoside has potent coronary vasodilating effects,6 we next assessed adenosine release in response to hypoxia, as well as the effects of specific blockade of adenosine receptors. As shown in Figure 4 , HCVD was also associated with an increase in adenosine release into the coronary effluent, but in contrast to the enhancement in cGMP spillover that occurred mostly in the hypoxic period, adenosine release increased more markedly in the first minute of reoxygenation (compare Figures 3B  and 4B ). In the presence of the nonselective adenosine receptor antagonist BW A1433, HCVD was markedly attenuated ( Figure 4A ). In contrast, hypoxic adenosine release was not modified by BW A1433 alone ( Figure  4B ) or in combination with NMA (data not shown), nor was hypoxic adenosine release modified by NMA, alone or in combination with L-arginine ( Figure 3C ).
Inasmuch as a facilitation of mechanical washout associated with the increase in coronary flow rate could contribute to the enhanced spillover of the putative did not reduce the hypoxic increase in cGMP overflow ( Figure 4C ). NMA (300 ,M) and BW A1433 (1 uM) were approximately equieffective in inhibiting HCVD in both spontaneously beating and paced hearts ( Figure 7A ). In contrast, indomethacin (10 ,uM) was a much weaker inhibitor in paced than in spontaneously beating hearts, independent of whether indomethacin was perfused alone (4.6±7.2% inhibition) or in combination with 300 ,uM NMA (34.8±7.7% inhibition) ( Figure 7A ). Fur- (58.1±5.1%, Figure 7A ). Excess L-arginine (1.2 mM) was as effective in antagonizing the inhibitory effects of NMA (300 ,uM) in paced hearts as in the spontaneously beating ones. Inasmuch as NMA (300 ,uM) combined with either BW A1433 (1 ,uM) or indomethacin (10 ,M) failed to inhibit HCVD by more than 72%, we next attempted to combine NMA with BW A1433 and indomethacin, to determine whether complete HCVD inhibition could be obtained. However, when hearts were perfused with BW A1433 and indomethacin together, cardiac contractile force rapidly failed, and this preempted the further addition of NMA to the drug combination, let alone the eliciting of HCVD. In any event, as shown in Figure 7 , the extent of HCVD inhibition with either NMA+BW A1433 or NMA+indomethacin was less than the sum of the inhibitory effect of each single drug, demonstrating a lack of synergism between the three drugs. Thus, even if it had been possible to use all three agents together, it is unlikely that complete inhibition of HCVD would have been obtained.
The question arose at this point as to whether our failure to observe synergism between NMA and BW A1433 on one hand and NMA and indomethacin on the other might be concentration related. To investigate this possibility, we lowered the concentrations of NMA and BW A1433 by factors of 3 and 10, respectively and combined these two agents with indomethacin 10 ,uM. As shown in Figure 7B , NMA (100 ,uM), BW A1433 (0.1 ,uM), and indomethacin (10 ,uM) 0.1 ,uM) also failed to reveal any synergism (data not shown).
Discussion
The purpose of our investigation was to assess whether arginine-derived NO is a mediator of HCVD. We have found that exposing the isolated guinea pig heart perfused at constant pressure to hypoxia for 1 minute results in a swift doubling of coronary flow rate and a rapid eightfold increase in cGMP overflow into the coronary effluent. Inasmuch as cGMP is a marker of NO production28,29 and the specific NO synthase inhibitor NMA30,31 antagonized the increase in coronary flow and the associated cGMP overspill (see Figures 2 and  3 ), our findings strongly suggest that NO is a mediator of HCVD. In further support of this, we found that excess arginine abolished the antagonistic effects of NMA on both coronary flow and cGMP spillover (See Figures 2  and 3) .
Although NMA causes a decrease in coronary flow in the isolated heart (see Table 1 ),20 the antagonistic effect of NMA on HCVD is not secondary to this effect. Indeed, when coronary vessels were constricted with the thromboxane analogue U46619, HCVD was unaffected (see Figure 3A) . Furthermore, the antagonistic effect of NMA on HCVD was independent: 1) of the ventricular rate, since NMA was as potent in spontaneously beating hearts as in those paced at a higher rate (see Figure 7) , and 2) of changes in coronary flow, since NMA also antagonized HCVD in an arginine-reversible manner in hearts perfused at a constant flow (see Figure 2B) . Nor was the effect of NMA and its reversal by arginine the consequence of a hypothetical progressive deterioration of the preparation; indeed, the magnitude of HCVD remained constant for at least 1 stabilization, i.e., within the duration of the pharmacological experiments (see Figure 1A) . HCVD was also associated with an increased adenosine spillover and was antagonized by the adenosine receptor blocker BW A1433 (see Figures 4 and 7) . The increased adenosine spillover was not a consequence of mechanical washout associated with the increase in coronary flow rate in response to hypoxia. Indeed, when the coronary flow rate was increased by pinacidil to the same extent as with hypoxia, adenosine spillover was actually decreased (see Figure 5) . Similarly, it is unlikely that the increase in cGMP spillover associated with hypoxia is due to mechanical washout rather than to an increase in NO production. Indeed, we found that NMA was highly effective in antagonizing HCVD even when coronary flow was kept constant (see Figure 2B) . Notably, the timing of adenosine overflow differed from that of cGMP, and the time courses of HCVD inhibition by BW A1433 and NMA were also different (compare Figures 3 and 4) . cGMP spillover peaked in the early phase of HCVD, whereas adenosine overflow reached its maximum in the immediate posthypoxic period. Moreover, whereas inhibition of NO synthase with NMA predominantly antagonized the early HCVD phase (see Figure 3A) , blockade of adenosine receptors with BW A1433 preferentially antagonized the late HCVD phase (see Figure 4A) . Hence 38 In view of our finding that the peak of cGMP spillover preceded that of adenosine, such a possibility would seem unlikely. Furthermore, the coronary-vasodilating effect of adenosine was not modified by NMA (see Figure 6 ), nor did BW A1433 modify the hypoxic cGMP spillover (see Figure  4C) . Conversely, NMA, alone or combined with arginine, did not modify adenosine release (see Figure 3C ). Hence, although NO and adenosine may both account for HCVD in the isolated guinea pig heart, it appears that NO does not mediate the coronary-vasodilating effect of adenosine, nor does adenosine affect that of NO. Moreover, the fact that cGMP spillover did not increase when adenosine receptors were blocked and that adenosine release did not increase when NO synthase was inhibited indicates the absence of reciprocal compensatory functions. Thus, our data suggest that NO and adenosine contribute to the early and late phases of HCVD, respectively, as independent and unrelated mechanisms.
The participation of vasoactive arachidonate metabolites in HCVD has long been sought and debated. Indomethacin was found to suppress HCVD in rats,'3 to diminish it in dogs,39 and to greatly decrease it or abolish it in isolated canine coronary microvessels40 as well as in hearts isolated from guinea pigs, rabbits,41 and rats.'4 Okada14 also found that HCVD in the rat heart was accompanied by an approximately twofold increase in the outflow of prostaglandin E2 and prostacyclin, which reached a peak after 1 minute of hypoxia.14 In contrast, indomethacin was reported not to abolish HCVD in the isolated rabbit heart9"0 and in the canine coronary vasculature in vivo."1 We have found that indomethacin inhibited HCVD by -35% in the spontaneously beating heart but was without effect when the ventricles were paced at a higher rate (see Figure 7A) . Presumably, this indicates that at faster heart rates cyclooxygenase-derived vasodilators are less important than adenosine. Indeed, adenosine is released in greater amounts as cardiac rate increases,6 and in fact, BW A1433 inhibited HCVD more effectively in paced than in spontaneously beating hearts (see Figure 7A) . In any event, our data do not exclude the participation of vasoactive prostanoids in the induction of HCVD in the isolated guinea pig heart perfused at constant pressure. However, the role of cyclooxygenase metabolites appears less relevant than that of NO and adenosine.
When we studied the effects of various antagonists in combination, we found that, irrespective of the drug concentrations, the extent of HCVD inhibition never exceeded, at best, the sum of the inhibitory effects of the single antagonists (see Figure 7 ). This indicates that NO, adenosine, and cyclooxygenase metabolites of arachidonic acid act as independent and nonsynergistic mediators of HCVD.
A complete inhibition of HCVD was achieved neither with maximal concentrations of NMA and BW A1433 nor with NMA, BW A1433, and indomethacin in combination. Maximal inhibition was :70%. Thus, other mechanisms must account for the remaining 30% increase in coronary flow. Purinergic (e.g., ATP) and peptidergic substances (e.g., calcitonin gene-related peptide, vasoactive intestinal peptide, and substance P) released from perivascular vasodilator nerves and acting directly on specific smooth muscle receptors without the requirement of NO release from the coronary endothelium42 could account for that portion of HCVD that is insensitive to NMA, BW A1433, and indomethacin. In fact, evidence for an ATP-induced coronary vasodilation in the isolated guinea pig heart, independent of NO production and of degradation of ATP to adenosine, has recently been published. 43 It has been claimed that HCVD can be mimicked in the isolated guinea pig heart by cromakalim, an opener of ATP-modulated potassium channels, and antagonized by glibenclamide, a blocker of the same channels, at concentrations not affecting the response to bradykinin,16 an NO-dependent coronary vasodilator. 44 These findings have been interpreted to suggest that opening of potassium channels in coronary vascular smooth muscle during hypoxia leads to membrane hyperpolarization and closing of voltage-gated calcium channels, with a consequent decrease in intracellular calcium and vasodilatation.16 Whether glibenclamide can also block both NO-and adenosine-induced coronary vasodilatation is controversial. 45 Thus, it is unclear whether the opening of ATP-sensitive potassium channels could function as a final common HCVD pathway for both NO and adenosine.
Adenosine is released from both coronary endothelial cells and cardiac myocytes upon exposure of the isolated guinea pig heart to hypoxia.5 The same could apply to NO. Indeed, not only the coronary endothelium but also endocardial cells and cardiac myocytes possess a constitutive calcium-calmodulin-dependent NO synthase.46,47 Thus, endothelium, myocardium, and even endocardium could all contribute to the rapid hypoxic release of NO. In contrast, vascular smooth muscle cells produce NO via a calcium-independent inducible form of NO synthase48; this process involves DNA transcription and mRNA translation and requires hours.49 Hence, it is unlikely that the coronary smooth muscle will contribute to the immediate NO production associated with HCVD.
What couples hypoxia to NO biosynthesis is presently unknown, but calcium could presumably be the intracellular signal, as probably occurs in response to other stimuli such as flow or shear forces.50 Sufficient calcium may enter endothelial cells through stretch-activated nonselective cation channels to serve a second messenger function,5' including activation of NO synthase followed by NO release, guanylyl cyclase stimulation, cGMP production, and vasorelaxation. In addition, shear stress activates a potassium current in vascular endothelial cells52; the resulting hyperpolarization provides an increased electrical driving force for a transmembrane Ca 2 influx53 with consequent activation of Ca2+-dependent NO synthase.
Similar processes could operate in response to hypoxia. Preliminary evidence for a rapid increase in intracellular free calcium in endothelial cells exposed to hypoxia has been reported.54 Ca21 may enter the endothelial cell membrane not only via leak, stretch-activated, and receptor-operated channels53 but also through three different kinds of voltage-gated Ca21 channels.55 Activation of these voltage-operated Ca2+ channels would require depolarization, which could result from a decrease in potassium conductance. Since guinea pig coronary endothelial cells have a relatively low resting membrane potential (--35 mV),56 it is more likely that the mechanism by which hypoxia could enhance intracellular Ca2`is an increase in potassium conductance, causing membrane hyperpolarization and thus an increase in driving force for Ca`+. Finally, it is not inconceivable that hypoxia may also directly activate Ca2+ channels coupled to Po2 sensors. Be that as it may, it seems reasonable that endothelial cells could act as Po2 sensors57 and transduce this signal into an increase in intracellular Ca 2+ necessary for NO synthase activation.
In conclusion, our data demonstrate that HCVD is associated with an early and rapid increase in cGMP spillover and a secondary increase in adenosine overflow. NO synthase inhibition with NMA antagonizes the early HCVD phase and the associated increase in cGMP spillover; excess arginine prevents the effects of NMA. Adenosine receptor blockade with BW A1433 antagonizes the second HCVD phase. It is plausible that endothelial cells function as Po2 sensors and that the signal is immediately transduced into a rise in intracellular Ca2+, NO synthase activation, and NOmediated vasodilatation. Adenosine, released from endothelial cells and cardiac myocytes as a hypoxic metabolite, sustains the vasodilatation initiated by NO. Prostaglandin E2 and prostacyclin could also contribute to the second phase of HCVD. Because NO synthase inhibition, alone or combined with adenosine and cyclooxygenase blockade, did not completely block HCVD, further mechanisms may be involved in HCVD (e.g., an increase in the "open probability" of ATP-sensitive K+ channels in coronary smooth muscle and mediator release from perivascular vasodilator nerves).
